Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 1999 November;51(11) > Minerva Ginecologica 1999 November;51(11):445-8





A Journal on Obstetrics and Gynecology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index




Minerva Ginecologica 1999 November;51(11):445-8


language: Italian

Chemotherapy in the treatment of carcinosarcoma of the ovary

Melilli G. A., Di Vagno G., Cormio G., Greco P., Fontana A., Carriero C., Loverro G., Selvaggi L.


Carcinosarcoma of the ovary is a rare neoplasm representing 1% of this organ malignances. The disease appears almost exclusively in advanced stage having an infavourable prognosis. Three patients affected by carcinosarcoma (MMMT) of the ovary admitted to our Operative Unit have been treated. All patients underwent surgery and subsequently chemotherapy. Two patients were affected by heterologous MMMT and were stage IV and IIIc respectively, the other one, affected by homologus MMMT, was stage IIIc. Stage IV patient was submitted to 6 cycles of CARBO+IFX+CDDP, second look and further 6 cycles of TAX. After 23 months she was submitted to colostomy for intestine occlusion. At the 35 months she died for cachexia and intestine occlusion. Stage IIIc heterologous patient was submitted to 6 cycles of CDDP+EPI+IFX+MESNA for 3 days; at 6 months from diagnosis she did not present any sign of disease. Stage IIIc homologus patient, affected by chronic renal insufficiency and submitted to dialysis, underwent 5 cycles of TAX and at 11 months from diagnosis presented partial response. Carcinosarcoma of the ovary, because of its rarity, and of the poor record of cases in the literature, is a much debated topic in particularitis complementary therapy. Opinions of the several authors are in contrast regarding the use of CHT+RT at the same time. Only RT after surgery does not seem to improve the survival of these patients. Personal experience, with the reported outlines, compared with survival, seems to confirm the use of CDDP and of IFX and to give new horizons to TAX, waiting for further findings.

top of page

Publication History

Cite this article as

Corresponding author e-mail